Warner Matthew A, Johnson Matthew L, Hanson Andrew C, Fortune Emma, Flaby Gerald W, Schulte Phillip J, Hazelton Valerie M, Go Ronald S, Beam W Brian, Charnin Jonathan E, Anderson Brenda K, Karon Brad, Cheville Andrea L, Gajic Ognjen, Kor Daryl J
Division of Critical Care Medicine, Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota.
Anesthesia Clinical Research Unit, Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota.
JAMA Netw Open. 2025 Mar 3;8(3):e252353. doi: 10.1001/jamanetworkopen.2025.2353.
Anemia is a common complication of surgery and acute illness that is associated with adverse clinical outcomes. The role of anemia prevention and treatment strategies in this setting remains unclear.
To evaluate the effect of a multifaceted anemia management bundle vs standard care on posthospitalization hemoglobin recovery and multidimensional functional outcomes in survivors of acute illness.
DESIGN, SETTING, AND PARTICIPANTS: This parallel group randomized clinical trial, known as the Practical Anemia Bundle for Sustained Blood Recovery, was conducted at postsurgical and medical intensive care units at a large US medical center. Critically ill patients (aged ≥18 years) with moderate to severe anemia (hemoglobin concentration <10 g/dL) were enrolled between March 2022 and November 2023. Participants were randomly assigned 1:1 to the intervention or standard care group. Intention-to-treat analyses were performed between July 2024 and January 2025.
The intervention bundle was delivered throughout the duration of hospitalization and included optimized phlebotomy practices, clinical decision support, and pharmacological anemia treatment with intravenous iron.
The primary outcome was the mean difference in hemoglobin concentration at 1 month after hospital discharge.
A total of 100 patients (median [IQR] age, 68 [61-72] years; 57 men [57.0%]; 65 [65.0%] with postsurgical admission to the intensive care unit) were enrolled during acute illness. Forty-nine patients (49.0%) were assigned to receive the intervention, and 51 (51.0%) were assigned to receive standard care. Hemoglobin concentration at 1 month after discharge was greater in patients receiving the intervention vs standard care (median [IQR], 12.2 [11.8-13.0] g/dL vs 11.5 [10.2-12.6] g/dL; adjusted mean difference, 0.69 [95% CI, 0.13-1.20] g/dL; P = .02).
This randomized clinical trial found that a multifaceted anemia prevention and treatment bundle was feasible, was well tolerated, and improved posthospitalization hemoglobin concentrations up to 3 months in critically ill adults. These findings can inform the design of future trials.
ClinicalTrials.gov Identifier: NCT05167734.
贫血是手术和急性疾病常见的并发症,与不良临床结局相关。贫血预防和治疗策略在这种情况下的作用仍不明确。
评估多方面贫血管理方案与标准治疗对急性疾病幸存者出院后血红蛋白恢复及多维功能结局的影响。
设计、地点和参与者:这项平行组随机临床试验,即持续血液恢复实用贫血方案,在美国一家大型医疗中心的外科和内科重症监护病房进行。2022年3月至2023年11月期间纳入了患有中度至重度贫血(血红蛋白浓度<10 g/dL)的重症患者(年龄≥18岁)。参与者按1:1随机分配至干预组或标准治疗组。2024年7月至2025年1月进行意向性分析。
干预方案在住院期间全程实施,包括优化静脉采血操作、临床决策支持以及静脉注射铁剂进行药物性贫血治疗。
主要结局是出院后1个月时血红蛋白浓度的平均差异。
共有100例急性疾病患者(年龄中位数[四分位间距],68[61 - 72]岁;57例男性[57.0%];65例[65.0%]入住重症监护病房的外科患者)入组。49例患者(49.0%)被分配接受干预,51例(51.0%)被分配接受标准治疗。接受干预的患者出院后1个月时的血红蛋白浓度高于接受标准治疗的患者(中位数[四分位间距],12.2[11.8 - 13.0]g/dL对11.5[10.2 - 12.6]g/dL;调整后平均差异,0.69[95%CI,0.13 - 1.20]g/dL;P = 0.02)。
这项随机临床试验发现,多方面贫血预防和治疗方案可行,耐受性良好,可使重症成人出院后血红蛋白浓度在长达3个月的时间内得到改善。这些发现可为未来试验的设计提供参考。
ClinicalTrials.gov标识符:NCT05167734。